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Context: Most girls with Turner syndrome (TS) have hypergonadotropic hypogonadism and need
hormonal replacement for induction of puberty and then for maintaining secondary sex charac-
teristics, attaining peak bonemass, and uterine growth. The optimal estrogen replacement regimen
is still being studied.
Evidence Acquisition: We conducted a systematic search of PubMed for studies related to TS
and puberty.
Evidence Synthesis: The goals of replacement are to mimic normal timing and progression of
physical and social development while minimizing risks. Treatment should begin at age 11 to 12
years, with dose increases over 2 to 3 years. Initiation with low-dose estradiol (E2) is crucial to
preserve growth potential. Delaying estrogen replacement may be deleterious to bone and uterine
health. For adults who have undergone pubertal development, we suggest transdermal estrogen
and oral progestin and discuss other approaches. We discuss linear growth, lipids, liver function,
blood pressure, neurocognition, socialization, and bone and uterine health as related to hormonal
replacement.
Conclusion: Evidence supports the effectiveness of starting pubertal estrogen replacement with
low-dose transdermal E2. When transdermal E2 is unavailable or the patient prefers, evidence
supports use of oralmicronized E2 or an intramuscular preparation.Onlywhen these are unavailable
should ethinyl E2 be prescribed. We recommend against the use of conjugated estrogens. Once
progestin is added, many women prefer the ease of use of a pill containing both an estrogen and
a progestin. The risks and benefits of different types of preparations, with examples, are discussed.
(J Clin Endocrinol Metab 103: 1790–1803, 2018)
The 2017 updated guidelines from the InternationalTurner Syndrome Consensus Group have been
published in the European Journal of Endocrinology (1)
and endorsed by the European Society of Endocrinology,
the Endocrine Society, the Pediatric Endocrine Society,
the European Society for Pediatric Endocrinology, the
European Society of Human Reproduction and Embry-
ology, the American Academy of Pediatrics, and the
Society for Endocrinology (United Kingdom). The
American Heart Association and European Society of
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Abbreviations: AMH, anti-Mu¨llerian hormone; BMD, bonemineral density; CEE, conjugated
equine estrogen; E2, estradiol; EE, ethinyl estradiol; FSH, follicle-stimulating hormone; GH,
growth hormone; LH, luteinizing hormone; OC, oral contraceptive; TD, transdermal; TS,
Turner syndrome; VTE, venothrombotic episode.
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Cardiology also had official delegates at the meeting. The
present paper expands on those guidelines specifically
relating to puberty and estrogen replacement.
Turner syndrome (TS) defines phenotypic females who
have one X chromosome and complete or partial absence
of the second X chromosome. TS is characterized by
physical features, including a classic facial appearance,
neck webbing, short stature, and lymphedema, as well as
ovarian insufficiency, sensorineural hearing loss, con-
genital cardiovascular disease, renal anomalies, some
neurodevelopmental disorders, and increased risk of
thyroid and celiac diseases. TS affects 25 to 50 girls per
100,000, and there is a very broad clinical spectrum of
presentation. Some individuals have all the aforemen-
tioned features and others have minimal features, with or
without short stature and ovarian insufficiency. The
karyotype in TS ranges from complete 45,X to forms of
mosaicism inwhich there is a normal (i.e., 46,XXor 46,XY)
cell line, and an abnormal second (or third) cell line (2).
TS is usually accompanied by hypergonadotropic
hypogonadism due to gonadal dysgenesis and ensuing
primary or secondary amenorrhea. Therefore, most pa-
tients with TS will need hormonal replacement therapy,
first for induction of puberty and then for maintaining
secondary sex characteristics, attaining peak bone mass,
and normalizing uterine growth for possible pregnancy
later. This review focuses primarily on estrogen hormone
replacement in the care of girls with TS.
The optimal estrogen replacement therapy regimen to
induce pubertal development and maintain beneficial
effects in adults is still being studied. A substantial body
of literature to date supports the effectiveness and the-
oretical benefits of starting pubertal estrogen replacement
with low-dose transdermal (TD) estrogen, although, to
our knowledge, there is no study to date of TD use from
initiation of puberty until adulthood. Theoretical benefits
of TD use include the more physiologic route of delivery,
avoiding first-pass effects in the liver that include the
accumulation of unphysiologic estrogens observed after
the oral route (3), and avoiding effects associated with a
procoagulation state (4) and increased risk of stroke (5).
We review estrogen forms, timing of replacement, dos-
ing, route of administration, duration of treatment, and
monitoring of treatment. We also review evidence relevant
to optimizing the outcome and minimizing the risk of
estrogen replacement in puberty as regards growth, lipids,
liver health, bone health, uterine health, and thrombosis
risk, as well as socialization and neurocognitive benefits.
Spontaneous Puberty in Girls With TS
Approximately one-third of girls with TS have sponta-
neous breast development that may progress to menarche,
occurring most often in girls with mosaicism (6, 7). Regular
menstrual cycles occur in;6% (8) of these young women.
Laboratory Markers of Ovarian Function
Elevated concentrations of gonadotropins, luteinizing
hormone (LH), and, particularly, follicle-stimulating
hormone (FSH) indicate ovarian failure (9, 10). FSH
concentrations are higher in girls with 45,X karyotype
compared with those with mosaic karyotype. LH and
FSH levels in girls with TS are elevated after birth, then
decline to levels similar to girls with normal ovarian
function during mid childhood, and rise again in the
peripubertal years (9, 11) or at the time of loss of previous
ovarian function. Low anti-Mu¨llerian hormone (AMH)
levels and undetectable inhibin B levels have been
reported to predict ovarian failure in TS (9, 12). In one
study, 70 girls with TS and 2406 girls without TS had LH,
FSH, and inhibin B concentrations measured before
estrogen treatment (9). Ovarian function was related to
whether girls had 45,X or amosaic karyotype. According
to the study data, undetectable inhibin B may predict the
absence of spontaneous puberty, but the specificity was
low. AMH in 120 girls with TS predicted no ovarian
function when levels were ,4 pmol/L (0.56 ng/mL) and
predicted ovarian function when levels were.19 pmol/L
(2.66 ng/mL) (12).
TreatmentOptions for Inductionof Puberty
and Maintenance of Feminization
Estrogen forms available for replacement
Estradiol (E2) is the natural form of estrogen that is
secreted and binds to the estrogen receptor in humans
(13). Ethinyl estradiol (EE) is a very potent synthetic E2
analog that is not metabolized to E2. It binds to estrogen
receptors a and b. EE has an ethinyl group covalently
attached at the 17a-position. EE is taken up in
unmodified form and retained by estrogen target tissues
for a longer time than is E2. The E2 precursor estrone acts
after being metabolized to E2. Equine estrogens, the
major components of the widely used conjugated equine
estrogens (CEEs), consist of .100 forms of estrogens of
different receptor affinity and potency. Estrogens are
metabolized in the liver bymicrosomal cytochrome P-450
with aromatic hydroxylation at either the C2 or C4
position as the major route. Other pathways include
formation of glucuronide conjugates and sulfation
(14–16).
Table 1 lists commonly available, lower-dose estrogen
treatments for pubertal induction and considerations for
their use. Table 2 lists some commonprogestin and estrogen/
progestin combination replacement options after pubertal
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induction is complete. The reader should be aware that
availability and trade names differ among countries. The list
is not all inclusive.We present data from various routes and
preparations but list other preparations for reference, with
the caution that studies have not been done in TS with each
preparation listed. Table 3 summarizes published low-dose
estrogen treatments for puberty induction in TS.
Timing and dose
The goals of replacement are to mimic the normal
progression of puberty in girls while maximizing growth
potential and minimizing risks. Delaying estrogen re-
placement may be deleterious to bone, uterine, and
psychosocial health parameters (28). To mimic normal
physical and social development, initiation of treatment
should begin at 11 to 12 years of age if levels of
gonadotropins are elevated or AMH concentration is low.
LH and FSH levels may be measured yearly starting at age
11, based on average age of pubertal onset. If gonado-
tropin concentrations are normal for age, observation
for spontaneous puberty is appropriate, with future
replacement therapy if gonadal failure occurs.
Incremental dose increases at ;6-month intervals can
mimic the normal pubertal tempo until adult dosing is
reached over 2 to 3 years. This theoretically translates into a
25% to 100% increase in dose every 6 months for four to
six dose changes between the initiation and adult doses
portrayed in the Table 1. However, no studies to date have
rigorously studied outcomes in relation to the rate of dose
increase for the different preparations.
In general, the studies summarized in Table 3 report
onset of breast budswithin 6months inmost girls (17, 18,
22, 23, 27). Each of these regimens results in pubertal
stage 4 breasts in an average of 2.25 years, which is
Table 1. Some Common Low-Dose Estrogen Treatment Options for Pubertal Induction in TS and
Considerations for Use
Preparationa
Doses Available,
Frequency, Route
Starting Dose
at Puberty
Dose Increase
Approximately Every
6 Mo to Adult Dosing Considerations for Use
Transdermal options (some
brands)
3–7 mg/d 25–100 mg/d See text on applying
patches
Menostar (Bayer) (matrix) 14 mg weekly TD One-half patch weekly Only used for low dosing,
not full replacement
Easiest way to give low
dose; once a week
dosing
Vivelle Dot (Novartis)
(matrix)
25, 37.5, 50, 75,
100 mg twice
weekly
One-quarter patch
weekly, or one
patch per month
(no patch other
3 weeks)
25–100 mg twice weekly Designed for twice-weekly
dosing, but can give once
per week to increase dose
more slowly
Vivelle Mini (matrix) 25, 37.5, 50, 75,
100 mg twice
weekly
Too small to cut
consistently
25–100 mg twice weekly Smaller size patch, but not
smaller dosing
Generic (different brands in
different countries)
25, 37.5, 50, 75,
100 mg twice
weekly
One-quarter patch
weekly, or one
patch per month
(no patch other 3 wk)
25–100 mg twice weekly Once-weekly dosing can be
used.
Estraderm (matrix) 50, 100 mg
twice weekly
Not small enough to
initiate puberty
50–100 mg twice weekly Cannot use to initiate
puberty
E2 gel 0.25 mg per pump One pump daily Only available in some
countries at the low doseEstragel (Ascend), 0.06% 0.75 mg E2 per
pump
Divigel (Vertical), 0.1% 0.25, 0.5, 0.1 mg
E2 per pump
Oral options
17b-E2 [e.g., Estrace
(Allergen), Cetura
(ACE)]
0.5, 1, 2, 4 mg/d One-half pill daily 1–4 mg/d Cheapest option, brands
vary by country
EE 2 mg/d 10–20 mg/d Not available in many
countries
Premarin (Pfizer) (a CEE) 0.3, 0.625, 0.9,
1.25 mg/d
One-half pill daily 0.625–1.25 mg/d Not available in many
countries, not
recommended based on
safety
Depot options
Depot E2 (E2 cypionate) 5 mg/mL 0.2 mg/mo 2 mg/mo Not available in Europe
aThe reader should be aware that availability and trade names differ among countries. The list is not all inclusive.
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similar to that in girls with TS who have spontaneous
puberty (1.9 years), aswell as in the general population (23).
Girls with TS are very short and have a very short adult-
height potential, typically 20 cm less than the average female
population in all countries studied. Growth hormone (GH)
treatment is US Food and Drug Administration–approved
therapy to promote growth in these girls, and the earlier it is
started, the better the growth promotion. However, the
expectations of intervention are modest. In general, GH
therapy results in a net gain of 1 cm/y of treatment (20, 29).
In girls in whom GH treatment has been delayed, consid-
eration of initiation of GH prior to low-dose estrogen is
particularly important to optimize growth. There are no
data to support the specifics of timing in such cases; rather it
is a matter of individualized judgment, balancing the desire
for taller height vs the desire for more rapid feminization.
When height is a greater concern, often GH treatment can
be initiated before low-dose E2; however, we recommend
that E2 not be delayed past 14 years of age. When femi-
nization is a greater concern, GH and E2 can be started
simultaneously.
Initiation with low doses of E2 is crucial to preserve
growth potential even if GH treatment has already been
initiated. Very low doses of EE and E2 do not interfere
with growth response toGH therapywhen started at#12
years of age (21, 24).
Progestins
Patients with TS have a normal uterus anatomy, so
progestin must be added once breakthrough bleeding
occurs, or after 2 years of E2 treatment, to minimize the
risks of endometrial hyperplasia, namely, irregular
bleeding and endometrial cancer associated with pro-
longed unopposed estrogen (30, 31).
Progestins are divided into several classes (Table 4) and
individual agents can bind to the progesterone receptor as
well as the androgen, glucocorticoid, and mineralocorti-
coid receptors (32). Each progestin exerts differential
effects on these various receptors and, accordingly, unique,
nonclass action effects. In addition to the progestational
effects, the 19-nor-progesterone derivatives are associ-
ated with androgenic action, medroxyprogesterone acetate
with glucocorticoid-agonistic action, and drospirenone
with antiandrogenic and anti-mineralocorticoid actions,
whereas progesterone is more specific to progestational
effects. The combined oral contraceptives (OCs) containing
progestins are divided into first-, second-, third-, and
fourth-generation OCs. First-generation OCs contain
50 mg of the estrogen mestranol and the progestogen
norethynodrel (e.g., Enovid; Searle). Most later-
generation pills use 20 to 35 mg of EE as the estrogen.
Second-generation progestogens include norethindrone;
its acetate, ethynodiol diacetate; and levonorgestrel.
Table 2. Some Common Progestin and Estrogen/Progestin Combination Replacement Options After Pubertal
Induction Is Complete
Adding Progestin
Options
Doses Available,
Frequency and Route
Not Needed to
Initiate Puberty
Add Once Bleeding
Occurs or After 2 Years Notes
Medroxyprogesterone
acetate
10 mg/d for 10 d Give with TD E2 or alone
for 10 d
Micronized progesterone
(Prometrium; AbbVie)
100 mg/d Give continuously with TD
E2
Less breast cancer
risk long term
Combined E2/progestin
sequential patch (some
brand options)
Do not use to initiate
puberty
Climara Pro (Bayer) E2 0.045 mg and levonorgestrel
0.015 mg/24 h
One patch weekly
Combipatch (Noven) E2 0.045 mg and norethidrone
0.14 or 0.25 mg/24 h
One patch weekly
Evo-Sequi (Janssen) E2 50 mg and norethisterone
acetate 170 mg/24 h
Two patches weekly
Combined E2/progestin
sequential pills
Do not use to initiate
puberty
Trisequens (Novo Nordisk) E2 2 mg and norethisterone
acetate 1 mg
1 pill/d
Divina plus Estradiolvalerate 2 mg and
medroxyprogesterone
acetate 10 mg
1 pill/d
Femoston (Mylan) E2 and dydrogesterone 1/10
or 2/10 mg
1 pill/d
Oral contraceptive pillsa Do not use to initiate
puberty
aThere are multiple types of oral contraceptive pills, which differ in estrogen dose, sequential vs continuous, and type and dose of progestin. The reader is
referred to the text to outline general principles.
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Third-generation progestogens include desogestrel,
norgestimate, and gestodene. Fourth-generation pills
include drospirenone. All OCs increase the risk of
venothrombotic episodes (VTEs). A recent guideline
(33) concluded that combinations of EE with the third- or
fourth-generation progestogens have a slightly higher risk
of VTE than those containing first- and second-generation
components.Micronized progesterone is associatedwith a
lesser risk (34).
Regimens of estrogen plus a progestin are either
combined sequentially with an estrogen for 21 to 25 days
and the progestin for only 10 to 14 days, or combined
with both sex steroids continuously. The estrogen is given
for up to 21 to 25 days to cause the endometrium to
Table 3. Summary of Published Studies of Low-Dose Estrogen Treatment of Puberty Induction in TS
Reference, Year Subjects
Estrogen Treatment,
Route and Dose Outcomes Height
Ankarberg-Lindgren
et al. (17), 2001
n = 8 girls with TS
(age 12–16 y) and
n = 7 with other
hypogonadism
TD E2 6–18 mg given just
12 h overnight
B2 in 3–6 mo in 75% of
girls on low-dose, and
B3 in 2 y on higher dose;
TD dose correlated with
serum E2 (P , 0.001)
No height data
Van Pareren et al.
(18), 2003
n = 60 girls with TS
with or without
spontaneous puberty
Oral E2 5 mg/kg 3 2 y →
7.5 mg/kg 3 1 y →
10 mg/kg after 4 y GH
B2 onset in 0.2 y on average No negative effect on height
or growth velocity vs
spontaneous puberty
Piippo et al. (19),
2004
n = 23 girls with TS E2 gel 0.1 mg 3 1 y →
0.2 mg 3 1 y → 0.5 mg 3
1 y → 1 mg 3 1 y →
1.5 mg 3 1 y
Pubertal advance about one
stage per year treatment
with 50% B2 at 6 mo
Adult height 153.1 6
4.8 cm (mean 6
standard deviation)
Soriano-Guillen et al.
(20), 2005
n = 704 girls with TS
with or without
spontaneous puberty
Oral EE 1–5 mg/d; oral E2
0.5 mg/d; TD one-quarter
of a 25-mg/d patch
No data on rate of pubertal
progression
Patients receiving TD E2
were taller than
those receiving oral
formulation by an
average 2.1 cm, but
shorter than spontaneous
Rosenfield et al. (21),
2005
n = 14 girls with TS,
compared with NCGS
registry, age 12–15 y
Depot E2 0.2 mg/mo with
increase of 0.2 mg every
0.5 y; GH also given
0.05 mg/kg/d
Half of girls B1 → B2 in 0.5 y,
and increased one stage per
0.5 y with each 0.2-mg
increase in dose. with 1 mg
dose: 100% B3–B5 by 2 y
and menarche in 62.5%
by 2.5 y
Lowest dose had greatest
GV; FH . PAH at start
of treatment; FH . GH
alone, growth not as
good as in TS with
spontaneous puberty
Nabhan et al. (22),
2009
n = 12 girls with TS,
age 11.3–17 y
Oral CEE (0.3–0.45 mg/d) vs
TD (25 mg/d for 6 mo →
37.5 mg/d for 6 mo)
B3–4 by 1 y in 83%; no
change in 17%; TD
group had greatest
increase in spine density,
BMD, uterine length and
volume
No height data
Bannink et al. (23),
2009
n = 56 girls with TS,
age 11–18 y
Oral E2 (5 mg/kg/d) 3 2 y,
with progression to 7.5 and
10 mg/kg/d
Breast stage progressed in same
timing as average Dutch
population: B1 → B2 in 0.2 y;
B1 → B4 in 2.1 y
No height data
Torres-Santiago et al.
(3), 2013
n = 40 girls with TS,
age 13–20 y
Oral E2 (average, 2 mg) vs
TD E2 (average, 0.1 mg),
dose titrated to plasma E2
No difference in body
composition, BMD,
or lipids between groups
No height data
Ross et al. (24), 2011;
Quigley et al. (25),
2014
n = 144 girls with TS
analyzed for growth;
n = 123 girls with TS
analyzed for puberty,
age 5–12.5 y
Oral EE: 25 ng/kg/d, 5–8 y;
50 ng/kg/d, .8–12 y; .12 y,
escalating from 100 ng/kg/d;
with or without GH
EE dose decreased for breast
development before age 12 y
or vaginal bleeding before
age 14 y; age of menarche
similar to general population;
earlier breast development for
girls who received the early
low dose
GH plus EE group height
SDS increase of 0.58
compared with increase
of 0.26 in GH alone
Perry et al. (26), 2014 n = 92 girls with TS, age
7–13 y
Oral EE: 2 mg/d year 1;
4 mg/d year 2; 6/8/10 mg/d
increases every 4 mo in
year 3
B1 → B2 in 0.65 y and to B4 in
2.25 y
Growth reported to be not
as good as with depot E2
Çakir et al. (27), 2015 n = 13 girls with TS, age
11–17 y
Oral E2 0.5 mg/d vs
TD 4.5 mg/d
B1 → B3–4 in 1 y BA advanced less with TD
(DCA/DBA 2.2 vs 0.58;
P = 0.005); GV greater
on TD at 1 y (4.35 vs
3.8; P = 0.022)
Abbreviations: B2, breast stage 2; B3, breast stage 3; B4, breast stage 4; BA, bone age; CA, chronologic age; FH, final height; GH, growth hormone; GV,
growth velocity; PAH, predicted adult height; D, change in; SDS, standard deviation score.
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become proliferative; the progestin in combination with
the estrogen induces the luteal phase of the endometrium.
Ten days of a progestin each month protects against
estrogen-induced endometrial hyperplasia, and 3 months
of combined continuous estrogen plus a progestin is
also protective (35). The combined sequential regimens
are associated with menstruation and are preferred in
younger women, whereas the combined continuous
regimens prevent uterine bleeding, an attractive factor for
older women. Intrauterine devices containing a progestin
block endometrial hyperplasia and unwanted bleeding,
can be used along with an estrogen, and can be especially
attractive for women with bleeding problems who are
taking either TD or oral combined formulations. Avail-
ability of products varies by country (Table 2).
Route: Oral vs TD Comparisons
E2 is normally secreted into the systemic circulation, the
liver receives the same dose as other somatic tissues, and a
systemic route of estrogen delivery is physiologic (13). In
contrast, estrogen given orally reaches the systemic cir-
culation only after absorption into the portal venous
system andmetabolism by the liver, thus exposing the liver
to a greater dose of estrogen than the rest of the body.
TD E2 is the most widely used of the physiologic E2
options, but the commercially available forms (patches
and gels) are designed for the adult female market and,
thus, the lowest-dose forms are four- to 10-fold greater
than are appropriate to deliver early pubertal E2 blood
levels. The main strategies that have been advocated to
fractionate TD E2 in a manner appropriate for early
puberty are based on different perspectives on normal
pubertal E2 physiology.
Currently, the lowest-dose patch commercially avail-
able delivers 14 mg/d E2, and the most widely used low-
dose patches deliver 25 mg/d. One method to deliver
lower doses is to cut the patch in smaller pieces. Patches
with a matrix design can be easily cut, whereas patches
with a reservoir technology should not be cut. The dis-
advantages of cutting patches are that handling the
smaller pieces may be difficult and cutting the patches is
not recommended by the products’ labels. However,
there is clinical experience with this, especially in Scan-
dinavia. There, a group showed that a fractionated patch
dose (one-quarter patch of a 25-mg dose approximately
equals 6.2 mg or even less) applied overnight mimicked
the normal, early-morning serum E2 peak and fell back to
baseline within a few hours of patch removal (17). If one
does not want to cut the patches, it has also been pro-
posed that cyclic administration of patches, commencing
with the application of a 14- to 25-mg patch for 1 week
monthlymay achieve similar results, althoughwe have no
data at this time with this method (21, 36). This proposal
comes from an expert committee of the Pediatric Endo-
crine Society, which recommended initiating cyclic
therapy with 25 mg/d TD E2 for 1 week and then
gradually increasing the duration of patch application to
3 weeks per month before increasing the patch size.
Support for this recommendation includes not only
considerations of convenience and manufacturer rec-
ommendations against patch fractionation but evidence
of efficacy of cyclic administration of depot systemically
delivered E2 (21). Evidence also exists that estro-
genization of the vaginal mucosa lags behind changes in
serum E2 by about 1 week (3, 37), suggesting that the
pituitary-ovarian axis activity normally commences with
attenuated cyclicity (38). Expert discussion of this
method, however, suggests that 1 week with and 3 weeks
without E2 would cause such variable changes in plasma
E2 concentrations during these 4 weeks that may not
mimic physiology. Additional data are needed before
conclusions can be made regarding the optimummode of
patch-application recommendation.
Two studies by Torres-Santiago et al. and Taboada
et al. have directly compared the TD and oral routes of E2
administration in teenagers (3, 39). The pharmacoki-
netics and pharmacodynamics of different doses of E2
given orally vs transdermallywere examined in a group of
girls with TS. TD E2 results in E2, E1, and bioestrogen
Table 4. Classification of Progestins
Classification Progestin
Natural Progesterone
Synthetic
Pregnane derivatives
Acetylated Medroxyprogesterone acetate
Megestrol acetate
Cyproterone acetate
Nonacetylated Chlormadinone acetate
Dydrogesterone
Medrogestone
19-Norpregnane derivatives
Acetylated Nomegestrol acetate
Nesterone
Nonacetylated Demegestone
Promegestone
Trimegestone
Nor-testosterone
Ethinylated estranes Norethindrone (norethisterone)
Norethindrone acetate
Ethynodiol diacetate
Norethynodrel
Lynestrenol
Tibolone
13-Ethylgonanes Levonorgestrel
Desogestrel
Norgestimate
Gestodene
Nonethinylated Dienogest
Drospirenone
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concentrations that are closer to normal and achieve
greater suppression of LH and FSH in lower doses
compared with normally menstruating girls without TS
(40). The metabolic effects of oral vs TD E2 were addi-
tionally compared in 40 late-teen girls with TS followed
for 1 year (3). The researchers found no differences in
body composition, bone mineralization, or plasma lipids
when the plasma E2 levels were titrated to those of
normally menstruating adolescents. Although no meta-
bolic differences were observed, oral estrogen was as-
sociated with a marked increase in conjugated estrogen
precursors such as estrone sulfate and increased serum
estrogenic bioactivity. This is concerning in the context of
the increased thromboembolic risk observed with oral
estrogen in epidemiological studies, although there are no
data to suggest that such problems are present in TS
(discussed later in this article). Some European countries
have approved an E2 gel (Table 1), but it is very difficult to
give a small enough dose for pubertal induction, and
there is only one study with data from girls with TS (19).
Depot route
Results of a randomized controlled trial showed that
early, depot E2 monthly injections at very low doses
stimulated normal pubertal growth and development in
conjunction with GH treatment (21). This remains a
viable alternative in the United States, although it is less
attractive because of the pain of injection.
Practical Considerations
Estrogen treatment is crucial for girls with TS, first to
induce puberty and then to maintain healthy levels for all
the reasons described here. Individualizing treatment
to optimize compliance is important, and helping girls
understand how easy it is to help them have breast devel-
opment consistent with their peers should be encouraged.
Based on literature and theoretical principles presented
here, we suggest the following practical approach to
feminize girls with TS: initiate puberty with low-dose TD
E2, when available, starting with half of a 14-mg patch
applied weekly, or a whole 14- or 25-mg patch for 1 week
per month at age 11 to 12 years (Table 1), and increase
every 6 to 12 months based on response and growth
potential. When not available, or for physician or patient
alternative preference, consider approaches discussed
earlier in this article and listed in Tables 1 and 2.
For the adult patient with TS, no long-term studies
have assessed the optimal dose, route, or duration of E2
treatment, to our knowledge. Our recommendations are
based on available data from women with TS and from
other hypogonadal patients. The effects of hormone
treatment in TSmay be different fromwhat is observed in
other patient populations, and caution is needed when
extrapolating data from postmenopausal studies (40).
With those cautions, the type and route must be nego-
tiated, taking into account the preference of the patient,
the size of the uterus (for possible oocyte donation), bone
and body composition assessed by dual-energy X-ray
absorptiometry, blood pressure, and quality of life, as
well as other considerations (discussed later in this arti-
cle). Adult TD replacement doses of 50 to 150 mg/d or
oral replacement doses of 2 to 4 mg of E2 will often be
sufficient. Oral progestin for 10 days per month (com-
bined sequential approach) or continuous progestin
regimens are suggested [analogous to the combined/
continuous methodology commonly used for meno-
pausal hormone therapy (41)]. If bleeding irregularities
occur or if the patient prefers, an intrauterine progestin-
coated device can be used together with either continuous
oral or TD E2. This will reduce bleeding irregularities and
often abolish bleeding and the need for systemic progestin
use. Close collaboration with a gynecologist with
knowledge of TS is very useful.
Duration
Once adult replacement doses are reached, treatment
should continue until the time of usual menopause,
around age 51 to 53 years, when the risks vs benefits of
continuing should be assessed, individualized, and
reassessed annually (35, 41). Combined estrogen and
progestin treatment duration is limited by increased risk
of breast cancer (42); however, there are no clinical or
epidemiological data relative to TS to suggest that breast
cancer is a problem. Actually, breast cancer seems to
occur less frequently amongwomenwith TS (1), although
diminished overall estrogen exposure may be a factor.
Estrogen therapy alone after menopausal age has a more
favorable risk–benefit ratio, allowing more flexibility
in duration, but is only indicated in women who have
undergone hysterectomy (43). There often will be a
continued need for education of the patient with TS to
explain the beneficial effects of hormonal replacement
therapy onmultiple organ systems to maintain adherence
to therapy.
Monitoring Treatment
Routine monitoring of serum LH or FSH levels is not
recommended during estrogen treatment, because levels
remain elevated in agonadal women until higher levels of
estrogen are given (44). The suppression of gonadotro-
pins was comparable after oral and TDE2 use when doses
were titrated to similar serum E2 levels (3). E2 mea-
surement using a sensitive assay (e.g., liquid or gas
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chromatography with tandem mass spectrometry)
allows dose titration if desired, though E2 levels for
optimal linear growth remain to be determined. Clinical
assessment, patient satisfaction, patient age, and, often,
residual growth potential are the primary determinants
for dose increase. If potential for taller stature is still
possible, girls may take lower estrogen doses for a longer
time. If girls are already older at initiation, the duration
until adult dosing may be shortened.
In adults, replacement TD doses of 50 to 200 mg/
d typically allowwomen to reach normal adult plasma E2
concentrations. The normal range of E2 in cycling women
is very wide, with early follicular phase levels as low as 20
to 40 pg/mL (;75 to;150 pmol/L) andmidcycle peak of
200 to 600 pg/mL (;730 to ;2200 pmol/L), and some
experts replace to these levels (3). When oral estrogen is
used, adult replacement doses of 2 to 4mg of E2will result
in normal circulating E2 levels [i.e.,;100 to;155 pg/mL
(;367 to ;568 pmol/L)] (44) and may lead to normal
levels of FSH and LH in some women (44, 45). However,
women with TS lack inhibin (46), so normalizing LH and
FSH levels is not the goal per se (47, 48). Optimizing all
the health benefits and minimizing the risks is the goal,
and it is important to remember that this must be
individualized.
Optimize Outcomes, Minimize Risks:
Growth, Lipids, Liver, Bone Health,
Uterine Health, and Thrombosis Risk
Estrogens and linear growth
Low-dose estrogen regimens do not appear to interfere
with growth response to GH therapy when begun at 11 to
12 years of age at low doses (21, 24, 26, 49). Ultra-low
dose oral EE (starting at 25 ng/kg/d at ages 5 to 12 years)
in childhood TS has been reported but is not currently
recommended, based on an increased risk of earlier
thelarche and no proven benefit to growth or pubertal
outcome (25).
A consistent effect of physiologic E2 replacement on
IGF-1 concentration has not been established (3). IGF-1
concentrations tended to be lower on oral than TD E2
[2166 12 vs 286 12 ng/mL (mean6 standard error) at
12 months; P = 0.059] (3), whereas an earlier study from
the same group showed no change in IGF-1 concentration
after oral or TD therapy (50). TD application caused a
decrease in IGF binding protein-3 and GH binding
protein compared with an increase in the former and
unchanged level of the latter after oral administration
(51). In contrast, contraceptive doses of oral EE are
known to suppress IGF-1 (52, 53). In a small study (n = 13
girls), bone age advanced less when using TDE2 than oral
E2 (change in chronological age divided by change in
bone age, 2.2 vs 0.58, respectively; P = 0.005). At the
same time, growth velocity was greater when using TDE2
than oral E2 at 1 year (4.35 vs 3.8 cm/y, respectively; P =
0.022), suggesting overall better growth (17).
Estrogens and Metabolism
Lipids
Although there are theoretical reasons to be concerned
about the relative systemic and hepatic hyperestrogenism
of low-dose oral estrogens vs low-dose TD E2, evidence
thus far does not indicate that the hepatic effects on lipids
or binding proteins cause an appreciable clinical difference
between the two forms of treatment (Table 5) (3, 39, 54).
With the exception of one study reporting signifi-
cantly elevated high-density lipoprotein cholesterol after
oral E2 (54), there were no significant differences in lipids
between groups with different routes of estrogen
administration (3, 39).
Estrogen deficiency in TS is associated with elevated
levels of intrahepatocellular lipids (62). Notably, whereas
liver enzymes are elevated in untreated TS (45, 51, 63, 64),
exogenous estrogen-progestin administered orally or
transdermally reduces these levels (45, 52, 65). However,
withdrawal of estrogen substitution did not influence
liver enzyme levels (66, 67). There was no evidence of
liver toxicity from estrogen replacement therapy (61).
Glucose and insulin
The risk of type 1 and type 2 diabetes mellitus is
increased in patients with TS across all ages (68).
However, there were no significant differences in glucose
(3), insulin tolerance (57, 59), fasting insulin concentra-
tion, protein turnover and lipolysis (50), osteocalcin or
highly sensitive C-reactive protein (3), bodymass index, or
waist-to-hip ratio (59, 60) between groups receiving TD vs
oral estrogen treatment (Table 5). Glucagon and insulin
levels (during oral glucose tolerance testing), as well as
insulin resistance, tended to be lower after evening oral E2
administration (0.3 to 0.5 mg/d) (58). Hyperinsulinemia
was suppressed to normal by both EE and CEE. A recent
study in 104 girls with TSwhowere followed up to 7 years
after GH therapy showed no negative influence of GH
treatment on b-cell function, which is also reassuring,
because most of these girls continued on estrogen
therapy (69).
Estrogens and bone density
Maintenance of bone health is crucial for women with
TS. Delaying estrogen replacement is deleterious to bone
health. Initiating and maintaining estrogen therapy
during puberty and adulthood as outlined in this article is
important for bone density accrual and prevention of
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fractures. In girls with TS, TD E2 administration (25 to
37.5 mg/d) has been reported as better than CEE (0.3 to
0.45 mg/d) for spine bone mineral density (BMD) in one
study [0.12 6 0.01 vs 0.06 6 0.01 g/cm2 (mean 6
standard error); P = 0.004] (22). Findings of a recent
study suggest a higher-than-usual oral dose (4 vs 2 mg)
during early adulthood improves body composition
(increased muscle mass) and increases bone formation
markers, which, although BMD was not increased
during the study period, in the long run could improve
overall bone health (70).
Some adult women with TS prefer combined estrogen
and progestin pill options for the sake of convenience
(71). Few studies have directly compared TD estrogen
regimens with oral regimens in women with premature
ovarian insufficiency, including patients with TS. The
better-powered studies indicated improved lumbar spine
density on a physiological sex steroid–replacement reg-
imen (100 to 150 mg E2 daily plus 400 mg of vaginal
progesterone 2 weeks per month) (48).
On the basis of these studies, the guidelines written by
the European Society of Human Reproduction and
Table 5. Estrogen Treatment and Metabolic Outcome Data
Reference, Year
No. of
Subjects Treatment Main Metabolic Measure Outcome
Jospe et al. (54), 1995 8 Oral E2 100 ng/kg/d vs TD E2 0.0125 mg/kg/d Oral, but not TD, increased serum HDL
Gravholt et al. (55), 1998;
Gravholt et al. (51),
1997
15 (oral) Oral: 2 mg/d E2 days 1–22, plus 1 mg/d
norethisterone acetate days 13–22, and 1
mg/d E2 days 23–28 vs TD E2 50 mg/d for
28 days plus oral 1 mg norethisterone days
13–22
No difference between oral and TD in insulin
sensitivity, body composition changes, 24-h
ambulatory blood pressure, IGF-1, liver
function test results, and lipid levels
8 (TD)
Gussinye´ et al. (56), 2000 12 TD E2 100 mg/d BMD and BMD z-score values significantly
increased; no significant differences in BMI,
calcium intake, and physical activity habits
Guttmann et al. (57),
2001
17 CEE 0.625 mg/d vs EE 30 mg/d Hyperinsulinemia was suppressed to normal by
both EE and CEE
Lipid profiles were normal on both regimens.
PTH and 1,25-dihydroxyvitamin D levels
increased while receiving HRT (EE . CEE),
and phosphorus decreased
Alkaline phosphatase, osteocalcin, and urinary
deoxypyridinoline cross-links were high while
off therapy; the former two suppressed to
high-normal levels on the EE regimen, but not
on CEE
Naeraa et al. (58), 2001 9 Morning oral E2 6–11mg/kg/d vs evening oral E2
6–11 mg/kg/d
During OGTT in the morning, glucagon and
insulin levels were lower after evening E2
administration, and insulin resistance tended
to be lower
Alves et al. (59), 2006 9 CEE 0.625 mg/d vs TD E2 (gel) 1.5 mg/d No difference in BMI, WHR, or insulin tolerance
between CEE and TD E2
During TD, tendency toward increased total
lean mass
Mauras et al. (50), 2007 11 Low-dose oral E2 0.5 mg/d LDL/HDL cholesterol responses were variable
among groups
Taboada et al. (39), 2011 10 Low-dose TD E2 0.0375 mg/d Neither oral nor TD E2adversely affected rates of
protein turnover, lipolysis, and lipid oxidation
rates or plasma lipids, fibrinogen, or fasting
insulin concentrations
High-dose oral E2 2.0 mg/d
High-dose TD E2 0.075 mg
Oral E2 0.5, 1, 2 mg/d for 2 weeks each vs TD E2
0.025, 0.0375, 0.05 mg/d for 2 weeks each
Torres-Santiago et al. (3),
2013
40 Oral E2 2 mg vs TD E2 0.1 mg Similar fat-free mass, % fat mass, BMD accrual,
lipid oxidation, resting energy expenditure rates
No significant changes in lipids, glucose,
osteocalcin, hs-CRP
Reinehr et al. (60), 2016 490 Oral vs TD (no details available) Duration and dose of estrogens, route of
administration did not correlate significantly
to changes of BMI SDS
See Table 3 legend for expansion of other abbreviations.
Abbreviations: BMD, bone mineral density; BMI, body mass index; CE, conjugated estrogen; HDL, high-density lipoprotein; HRT, hormone replacement
therapy; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; OGTT, oral glucose tolerance test; PTH, parathyroid hormone; WHR,
waist-to-hip ratio.
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Embryology favored TD E2 for women with premature
ovarian failure and commented that OC pills may be
appropriate for some women but effects on BMD are less
favorable (72–74). More comprehensive long-term
studies will be necessary to confirm these results and to
examine fracture rates.
Estrogens and uterine growth
Data on the influence of different routes of estrogen
therapy on uterine volume are still inconclusive because
route, dose, age at onset of treatment, and duration of
treatment all influence uterine growth (22, 23, 75–79).
However, it is clear the longer the duration of treatment
and the higher the dose of estrogen, the better the chances
of normalizing uterine size, which is important only if
pregnancy options are pursued.One study in 12 girls with
TS reported uterine length was significantly greater with
TD E2 treatment (25 to 37.5 mg/d) compared with CEE
[0.3 to 0.45mg/d; 4.136 0.39 vs 1.986 0.39 cm (mean6
standard deviation), respectively; P = 0.003] and uterine
volume greater [22.2 6 4.4 vs 4.0 6 4.4 mL (mean 6
standard deviation), respectively; P = 0.02] (78). Higher-
than-usual doses are often necessary before oocyte do-
nation, where oral doses up to 8 mg have been used for up
to 2 years to achieve satisfactory uterine growth (80).
Estrogens/progestin therapy and cardiovascular risk
Although, to our knowledge, there have been no
studies in children, or in women with TS, we recommend
against CEE use in view of thromboembolic and car-
diovascular disease risks reported in postmenopausal
women, especially in the first year of treatment using oral
estrogen, and in women with existing risk factors like
obesity (4, 5, 55, 81, 82).
E2 replacement therapy, oral or TD, lowers blood
pressure (55, 81, 82), although E2 causes salt and water
retention (83). This contrasts with EE-containing con-
traceptives, which raise blood pressure significantly unless
they contain an anti-mineralocorticoid progestin (84).
Recent reports have indicated no increased risk of
stroke with progesterone, pregnane derivatives, or nor-
testosterone derivatives (5, 85). However, norpregnane
derivatives were found to increase risk (5). Studies have
not been done in TS comparing various progestin options.
Several studies examining both oral E2 and oral
conjugated estrogens vs TD E2 replacement in the post-
menopausal setting have shown increased thromboem-
bolic risk, especially in the first year of treatment in the
oral group, that is more pronounced in women with
existing risk factors such as obesity (5, 44, 86). Studies
directly comparing thromboembolic risk in women with
TS have not been done, to our knowledge.
Screening for thromboembolic risk, through mea-
surement of Factor V Leiden and prothrombinase levels,
should be done in girls with a personal or family history
of VTE; however, routine screening is not recommended,
and screening is done only to educate the family about
risks, not to postpone estrogen therapy (87). TD estrogen
is the preferred treatment in these girls.
Socialization and neurocognitive benefits
Estrogen replacement in girls with TS may improve
motor speed and verbal and nonverbal processing time
compared with placebo-treated patients with TS (88, 89).
In adolescents with TS, oral estrogen therapy improved
self-reported self-esteem and psychological well-being
over time. At the same time, these patients’ parents re-
ported improvement in problem behaviors (90). Data on
adults with TS have not been so optimistic. Adults with
TS had relative difficulty with measures of spatial and
perceptual skills, visual-motor integration, affect recog-
nition, visual memory, attention, and executive function.
These deficits were apparent in women with TS despite
evidently adequate estrogen treatment (91, 92). Age of
onset of puberty influenced sexual experience in one
study (93) but not in another (94). A more recent follow-
up report suggests that women with TS face more
challenges in areas of sexual confidence and self-
esteem (95).
The young women with TS who reached normal
height and had age-appropriate pubertal development
reported normal health-related quality of life; satisfaction
with breast development (and height) had a positive in-
fluence on several health-related quality of life scales (96).
Puberty should be induced at a physiologically appro-
priate age in patients with TS to optimize self-esteem,
social adjustment, and timing of initiation of the patient’s
sex life. However, one study showed that neither estrogen
use nor age of puberty influenced sexual function in
patients with TS (94).
Oxandrolone effect on puberty
Oxandrolone is a nonaromatizable weak androgen
with direct growth-promoting effects. Low-dose oxan-
drolone acted synergistically with GH to increase linear
growth in several well-controlled studies (48, 97–99).
However, oxandrolone may also increase hirsutism and
clitoral size slightly, slow pubertal progression modestly
(by 1.3 years), and delay menarche in response to es-
trogen replacement (100). These effects are usually minor
and/or transient. Results of one study indicated normal
adult breast size is subsequently attained as oxandrolone is
discontinued and adult estrogen replacement is instituted
(101). Pubic-hair stage was not affected. Therefore, a
reasonable suggestion is that treatment with oxandrolone,
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0.03 to 0.05 mg/kg/d (maximum, 2.5 mg/d), starting from
the age of 10 years onward be considered as adjunctive
therapy only in very short girls with TS (100, 102).
Future Research
Only limited data from random controlled trials are
available nowon girls with TS regarding estrogen treatment
options, as discussed. There continues to be a paucity of
data from girls and women with TS regarding the regimens
discussed in this article and long-term compliance. Ques-
tions for future research include the following eight: (1)
What is the optimal protocol for pubertal induction, in-
cluding dose, route, and rate of progression? (2) What are
the optimal circulating levels of E2 during each phase of
pubertal induction? (3) What is the optimal dosing, prep-
aration, and timing of progestin-induced uterine bleeding?
(4) How long should E2 treatment be continued in women
with TS? (5) What are the optimal method and timing for
monitoring bone health in women with TS? (6) What is the
optimal regimen to promote uterine growth? (7) If anOC is
used for treatment, which are preferable inwomenwith TS?
and (8) What is the effect of OC pill placebo days on the
hormonal milieu in women with TS?
Conclusion
In summary, we suggest that estrogen replacement should
mimic normal physical and social development for timing
and progression of puberty, starting between 11 and 12
years of age and increasing over 2 to 3 years. This regimen
improves socialization and growth, and optimizes uterine
and bone health. Neurocognitive benefits are inconclusive.
When available, low-dose E2 administered by a
systemic route is preferred, and evidence supports its
effectiveness and theoretical benefits. When TD E2 is not
available, or compliance is an issue, evidence supports use
of oral micronized E2 or depot E2 preparations. Only
when these forms of E2 are unavailable should other
forms of estrogen be prescribed. Progestin should be
added once vaginal bleeding occurs or after 2 years of
estrogen treatment. At that time, some women prefer the
ease of use of an oral combination of estrogen and
progestin. Some preparations are safer than others, and
availability varies by country, but, ordinarily, the benefit
of good compliance to a chosen regimen outweighs the
risks. Treatment is monitored by patient satisfaction and
growth and development measures.
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